Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD)

Trial Profile

Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Bortezomib (Primary) ; Rituximab (Primary)
  • Indications Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2016 Planned End Date changed from 1 April 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 12 Apr 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 12 Apr 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Sep 2011 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top